NICO Corporation is set to launch the new Myriad SPECTRA System, a device for fluorescence-guided surgical removal of high-grade glioma brain tumours.

The new handheld technology is designed to assist surgeons in the fluorescence-guided surgical removal of Grade III and IV gliomas.

It can deliver white light for improved visualisation of tumours and clots, as well as blue light for supporting fluorescence-guided surgical removal of gliomas when used with compatible surgical microscopes.

The Myriad SPECTRA System offers a unique combination of illumination, resection, collection, and biological preservation of tissue.

It is applicable for surgeries addressing brain tumours and intracerebral haemorrhages (ICH), which are considered the most severe and costly strokes. The system supports minimally invasive and open craniotomy surgical approaches.

NICO plans to launch the device at the upcoming American Association of Neurosurgical Surgeons (AANS) Annual Scientific Meeting in Chicago.

The device's multi-functional capabilities allow surgeons to switch effortlessly between full-spectrum white light and supplemental blue excitation light, enhancing the surgical view without compromising the placement of surgical optics.

It recently received clearance from the US Food and Drug Administration and is also registered for sales and clinical use with the UK’s Medicines and Healthcare products Regulatory Agency.

NICO CEO and president Jim Pearson said: “Surgeon workflow and clinical efficiencies are critical benchmarks in today’s healthcare standards.

“We are excited to provide neurosurgeons with unique technologies that can significantly assist them in delivering the most advanced patient care while also benefitting from greater efficiencies in the operating room.”